|
Post by cretin11 on Feb 11, 2019 15:51:01 GMT -5
I absolutely think that Alfred E. Mann was instrumental in the creation of Receptor Life Sciences. Whether there are contractual ties to MannKind is unknown but I think that Mann may have had concerns about cannabis and its impact on Afrezza if MannKind were to begin development of cannabis-based therapeutics. Read more: mnkd.proboards.com/thread/10936/rls?page=4#ixzz5fEtnOYdmAnd they live rent free. I can’t see any scenario where they bought us . Just the same way that CYTR created Centurion to extract its LADR candidates from the parent company, I suspect MNKD will produce a similar spin-off to extract its Technosphere candidates from the MNKD parent company. This way if Afrezza proves to be a commercial failure and the franchise accumulates significant debt, the rest of the pipeline won't have to sink with that ship. The key question will be what percentage of ownership will current investors get in the spin-off in exchange for the rights to the IP, and will it go public or remain private? I suspect that will never happen.
|
|
|
Post by mnholdem on Feb 11, 2019 17:52:58 GMT -5
The fact that Al Mann was not invested or affiliated with RLS as a startup company is not sufficient reason to think he was not personal familiar with its financial backers. Mann was definitely involved in negotiating the Agreement and he had many acquaintances throughout the medical industry. I doubt that RLS just called MannKind out of the blue. Also, for those versed in legalese, a company PR stating that there was no affiliation between Al Mann and RLS was meant to address the concern that Mann formed RLS. He didn't. That statement does not eliminate the possibility of MannKind acquiring RLS at a future date. This is solely my opinion and there is, of course, only circumstantial evidence to support it.
|
|
|
Post by sportsrancho on Feb 11, 2019 18:05:46 GMT -5
Since they work out of Danberry there is no other company connected to them in the way we are.
|
|
|
Post by #NoMoreNeedles on Feb 11, 2019 18:41:00 GMT -5
Kelly Kraft from MannKind (15 years) just joined RLS > Check her LinkedIn page!
|
|
|
Post by lennymnkd on Feb 11, 2019 18:50:33 GMT -5
Kelly Kraft - Vice President, Product Development - Receptor Life Sciences | LinkedIn LinkedIn › kelly-kraft-bb451915 View Kelly Kraft's profile on LinkedIn, the world's largest professional community. Kelly has 3 jobs listed on their profile. See the complete profile ... MannKind Corporation. June 2003 – February 2019 15 years 9 months .
|
|
|
Post by mango on Feb 12, 2019 20:24:15 GMT -5
FDA is underway with reforming their regulatory framework to modernize oversight of dietary supplements. Additionally, FDA is expected to establish pathways permitting hemp-derived ingredients in food, beverages, and dietary supplements. Hemp was exempted from the definition of marijuana in the CSA following the passing of the 2018 Farm Bill The definition of Hemp: HEMP.—The term ‘hemp’ means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.With Hemp now being federally legal, FDA must play catch up. Under the FD&C Act, it remains unlawful for Hemp-derived CBD to be an ingredient in food stuffs and dietary supplements. Receptor appears to have plans, based on their patents and trademarks, to develop and commercialize nutritional supplements so this could get interesting. Does Receptor have plans to develop a generic version of Nabilone (Cesamet)? Receptor mentions nabilone in their patent claims: CLAIMS What is claimed is: 1. A composition comprising: nabilone, and sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), wherein the SNAC and the nabilone are present at a ratio (w/w) of between 1 :1 and 100: 1. patentscope.wipo.int/search/en/detail.jsf?docId=WO2018129097&tab=PCTCLAIMS&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28andrea+leone-bay%29&recNum=4&maxRec=360www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm088722.pdfwww.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628988.htmwww.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631065.htmwww.wyden.senate.gov/imo/media/doc/011519%20FDA%20CBD%20Hemp%20Letter.pdfwww.votehemp.com/wp-content/uploads/2018/12/FarmBill-CRPT-115hrpt1072.pdfwww.cannalawblog.com/senators-push-for-updates-to-fda-regulation-of-cbd-food-products-and-dietary-supplements/
|
|
|
Post by mango on Mar 13, 2019 0:12:34 GMT -5
|
|
|
RLS
Mar 13, 2019 0:20:22 GMT -5
Post by goyocafe on Mar 13, 2019 0:20:22 GMT -5
Yep! “...of the future” is spot on.
|
|
|
RLS
Mar 13, 2019 0:30:05 GMT -5
Post by mnkdfann on Mar 13, 2019 0:30:05 GMT -5
We all knew that someone had to design the website for RLS. Apparently RLS went with Third Hatch, a local 'small Seattle-based company' (presumably cheap), that has used pretty much the same template for all (four?) of its clients. Down the road, especially if RLS ever plans to do an IPO, hopefully it will upgrade.
(That's not to say that the site looks bad ... just sort of basic and interchangeable)
|
|
|
Post by mango on Mar 13, 2019 0:36:35 GMT -5
We all knew that someone had to design the website for RLS. Apparently RLS went with Third Hatch, a local 'small Seattle-based company' (presumably cheap), that has used pretty much the same template for all (four?) of its clients. Down the road, especially if RLS ever plans to do an IPO, hopefully it will upgrade. (That's not to say that the site looks bad ... just sort of basic and interchangeable) Arthur Rubinfeld probably had something to do with it... www.thirdhatchweb.com/airvisionI like this RLS website. 3rd Hatch says that it is primarily intended for potential investors and future partners. So the site isn't really meant to attract us, at least not right now anyway.
|
|
|
Post by mytakeonit on Mar 13, 2019 13:28:12 GMT -5
Heck ... my daughter's credit card has looked like that for years !
|
|
|
RLS
Mar 18, 2019 11:11:57 GMT -5
lakon likes this
Post by bigchungus91354 on Mar 18, 2019 11:11:57 GMT -5
We all knew that someone had to design the website for RLS. Apparently RLS went with Third Hatch, a local 'small Seattle-based company' (presumably cheap), that has used pretty much the same template for all (four?) of its clients. Down the road, especially if RLS ever plans to do an IPO, hopefully it will upgrade. (That's not to say that the site looks bad ... just sort of basic and interchangeable) Arthur Rubinfeld probably had something to do with it... www.thirdhatchweb.com/airvisionI like this RLS website. 3rd Hatch says that it is primarily intended for potential investors and future partners. So the site isn't really meant to attract us, at least not right now anyway. Why aren't we potential investors?
|
|
|
Post by mango on Apr 8, 2019 17:08:49 GMT -5
|
|
|
RLS
Apr 8, 2019 17:12:09 GMT -5
via mobile
mango likes this
Post by uvula on Apr 8, 2019 17:12:09 GMT -5
I hope the eighth time is successful.
|
|
|
RLS
Apr 8, 2019 19:19:36 GMT -5
Post by ltta on Apr 8, 2019 19:19:36 GMT -5
Is this our RLS??? Looks like it might be a different company.
It's for a consulting firm and owner name is Receptor Holdings, Inc. 3211 W. McGraw St. Seattle, Washington 98139.
Not Receptor Life Sciences, Inc. CORPORATION WASHINGTON 2578 Constance Drive W Seattle WASHINGTON 98199
|
|